Genmab A/S Sees Unusually Large Options Volume (NASDAQ:GMAB)

Key Points

• Genmab saw an unusually large surge in call-option activity: Traders bought 41,576 call options, 3,570% above the typical volume of 1,133.
• GMAB shares rose to $35.67 and traded near their 12-month high of $35.91, while the company reported quarterly EPS of $0.54 and revenue of $1.16 billion, beating analyst expectations.
• Wall Street remains broadly bullish: Analysts give Genmab a consensus “Moderate Buy” rating with an average price target of $39.50, and several firms have set targets between $40 and $43.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) saw some unusual options trading on Wednesday. Stock traders bought 41,576 call options on the company. This represents an increase of 3,570% compared to the typical volume of 1,133 call options.

Genmab A/S Stock Performance

Shares of GMAB stock traded up $0.10 during trading hours on Wednesday, hitting $35.67. The company's stock had a trading volume of 5,154,396 shares, compared to its average volume of 2,098,102. The company has a 50 day moving average of $32.54 and a 200 day moving average of $28.86. The stock has a market cap of $22.26 billion, a PE ratio of 28.09, a price-to-earnings-growth ratio of 1.93 and a beta of 0.84. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $35.91.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The firm had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.12 billion. On average, sell-side analysts forecast that Genmab A/S will post 1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently modified their holdings of GMAB. Integrated Wealth Concepts LLC acquired a new stake in Genmab A/S during the second quarter worth about $31,000. V Square Quantitative Management LLC purchased a new stake in Genmab A/S in the 1st quarter worth approximately $34,000. MidFirst Bank purchased a new stake in Genmab A/S in the 4th quarter worth approximately $56,000. Nykredit A S acquired a new stake in shares of Genmab A/S during the 2nd quarter worth approximately $58,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Genmab A/S by 39.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 3,032 shares of the company's stock worth $93,000 after purchasing an additional 854 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Weiss Ratings upgraded Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday, September 1st. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Genmab A/S in a research note on Monday, September 14th. New Street Research set a $43.00 target price on shares of Genmab A/S in a research report on Wednesday, July 22nd. Guggenheim upped their price target on shares of Genmab A/S from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Finally, TD Cowen raised shares of Genmab A/S from a "hold" rating to a "buy" rating and raised their price target for the stock from $32.00 to $43.00 in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $39.50.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab's portfolio includes products developed through partnerships as well as internally discovered candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.